Injection of skeletal myoblasts with genetic modifications to upregulate the expression of VEGF was reported to effectively treat acute myocardial infarction through vasodilatory and angiogenic effects (Suzuki et al., 2001; Haider et al., 2004). This evidence concerns the gene VEGFA and myocardial infarction.